Oppenheimer Maintains Outperform on CRISPR Therapeutics, Lowers Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on CRISPR Therapeutics (CRSP) but lowers the price target from $102 to $95.

May 10, 2024 | 4:47 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer maintains an Outperform rating on CRISPR Therapeutics but lowers the price target from $102 to $95.
While the reduction in price target could suggest a tempered outlook, the maintenance of an Outperform rating indicates continued confidence in the company's fundamentals. This mixed signal could lead to neutral short-term price movement as investors weigh the implications.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100